Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease
Current guidelines advise to maintain immunomodulators and biologicals in pregnant patients because relapse of inflammatory bowel is associated with unfavourable pregnancy outcome. With the exception of Methotrexate, IBD therapy seems not to be related to an increase of congenital malformations or infections requiring hospitalisation of the babies, although the effect the on the developing immune system of the exposed infants remains unknown. In this review we will focus on the effect of IBD drugs on health-related outcomes in children taking into account possible long-term effects of biologicals and immunomodulators, which are transferred across the placenta.
|Keywords||Anti-integrins, Anti-interleukin 12/23, Anti-TNFα, Child, Immune system, Inflammatory bowel disease, JAK inhibitor, Pregnancy outcome, Vaccination|
|Persistent URL||dx.doi.org/10.1016/j.bpg.2019.101665, hdl.handle.net/1765/123960|
|Journal||Best Practice and Research in Clinical Gastroenterology|
Wieringa, J.W, & van der Woude, C.J. (C. J.). (2019). Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Practice and Research in Clinical Gastroenterology. doi:10.1016/j.bpg.2019.101665